Study identifier:SD-039-0688
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy and safety of Symbicort (budesonide/formoterol 80/4.5 mcg, 2 inhal. b.i.d.) compared to Pulmicort (budesonide 100 mcg, 2 inhal. b.i.d.) and Pulmicort (budesonide 100 mcg, 2 inhal. b.i.d.) plus Oxis (formoterol 4.5 mcg, 2 inhal. b.i.d.) all delivered via Turbuhaler in steroid using asthmatic children. A double-blind, double-dummy, randomised, parallel-group, phase III, multicentre 12-week study.
asthma
Phase 3
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|